Levo Therapeutics has a singular focus – understanding the pathophysiology of Prader-Willi syndrome to advance treatments that will make a difference in the lives of patients and their families.
Exploring a Potential New Prader-Willi Syndrome Treatment
Our Phase 3 trial evaluated LV-101 (intranasal carbetocin) as a potential treatment for hyperphagia and anxiousness and distress behaviors in individuals with Prader-Willi syndrome. Learn more about the trial here (NCT03649477).
Looking to the Future of Prader-Willi Syndrome Treatment
Our lead candidate is LV-101 (intranasal carbetocin). We also are working to develop an earlier stage pipeline that builds on the emerging science of metabolic hormone regulation and gene activation in Prader-Willi syndrome.
PWS: A False State of Starvation
Prader-Willi syndrome is complex and presents a unique set of challenges reflecting a false state of starvation. This includes anxiety, compulsivity, life-threatening hyperphagia, mild to moderate levels of intellectual disability, growth hormone deficiency, and a high risk of obesity. Occurring in approximately 1 in 16,000 births, the underlying cause of Prader-Willi syndrome is the lack of expression of paternally inherited genes on a small part of chromosome 15.